AF4-MALS

Asymmetrical Flow Field-Flow Fractionation (AF4) is a high-resolution, gentle, size-based separation technique used to characterize macromolecules and nanoparticles in a membrane-bound, open-channel environment. When coupled with Multi-Angle Light Scattering (MALS), UV, and differential Refractive Index (dRI) detectors, AF4-MALS enables absolute molar mass, size, and composition analysis of viral vectors and lipid-based nanoparticles. For AAV products, AF4-MALS is primarily applied during development as a key characterization and orthogonal method to evaluate aggregation and capsid heterogeneity (e.g., empty/full capsid ratio).

• Legacy:
  Size Exclusion Chromatography (SEC) has long been used for aggregate analysis but can underestimate aggregates due to shear stress and on-column adsorption.

• Established Standard:
  AF4-MALS offers shear-free, column-free separation and is now increasingly adopted orthogonal method for aggregation and particle characterization in AAV and LNP development.

• Future Direction:
  Method automation, streamlined SOPs for broader use in regulated environments, and advanced data modeling tools (e.g., ASTRA® and proprietary AI-assisted tools) are ongoing areas of development.

AF4 Separation:
Particles are fractionated by hydrodynamic size as they flow through a flat channel with a semi-permeable membrane at the bottom. A perpendicular cross-flow pushes particles toward the membrane. Smaller particles diffuse away into faster-moving streamlines and elute earlier than larger particles.

MALS Detection:
As particles elute, they pass through a MALS detector which measures scattered light intensity at multiple angles. This enables calculation of absolute molar mass and radius of gyration (Rg) without external standards.

UV and dRI Detection:

• UV detects protein (capsid) and nucleic acid content.

• dRI measures the total mass concentration.

• Together, they allow composition deconvolution (e.g., AAV protein-to-genome content estimation).

• Output: A fractogram showing the overlaid signals from the MALS, UV, and dRI detectors versus elution time. A plot of the calculated molar mass for each eluting slice across the peaks is generated.
• Interpretation: Peaks are identified as empty capsids, full capsids, and high-molecular-weight species based on their elution time and measured molar mass. The area of each peak is used to calculate the percent distribution of these species, which provides the aggregate content and full/empty ratio.

• Shear-Free Separation: Reduces risk of particle damage or loss.

• Broad Size Range: Can resolve capsid aggregates and nanoparticle distributions in a single run.

• Absolute Sizing: No reliance on calibration standards.

• Multi-Detector Integration: Enables deeper insight into particle composition and behavior.

• Low Throughput: ~1 sample/hour in typical setups.

• Complex Method Development: Requires optimization of flow rates, membrane selection, and channel height.

• Specialist Operation: Interpretation of light-scattering data demands expert users and validated software pipelines.

As a characterization method, AF4-MALS undergoes formal method qualification to demonstrate it is fit for its intended purpose.

• System Suitability: Performance is typically verified using a well-characterized standard (e.g., a protein monomer or a nanoparticle standard) to confirm detector performance and elution consistency.
• Robustness: Qualification studies assess the impact of small, deliberate changes in method parameters (e.g., cross-flow rate, channel flow rate) on the results.
• Fit-for-Purpose Assessment: The method's precision and accuracy for measuring the key outputs (e.g., % aggregate, molar mass) are determined to ensure the data is reliable for characterization and comparability studies

Cross-laboratory comparability with AF4–MALS depends on tightly controlled channel/membrane selection, carrier composition/ionic strength, and cross-flow programs, plus detector normalization and verified inputs (e.g., concentration, dn/dc). To benchmark performance, labs commonly run well-characterized reference materials alongside samples: for proteins, the NIST monoclonal antibody (NISTmAb) RM 8671 is widely used to evaluate separation and aggregation measurements by AF4-UV-/MALS/EAF4; its intended use is method performance evaluation for mAbs.

For nanoparticles, NIST gold nanoparticle RMs (RM/SRM 8011–8013) and related sub-micrometer particle standards provide traceable checks on size measurement workflows and AF4–MALS system performance.

In AAV programs, standardization is still maturing: NIST’s recent interlaboratory study on empty/full quantification underscores the need for harmonized methods and controls, while commercial AAV reference materials (empty and full capsids) are used for assay development, bridging, and system suitability until formal public reference materials emerge.

• AAV Gene Therapy: Numerous publications and technical notes from instrument manufacturers, such as Wyatt Technology, demonstrate the successful use of AF4-MALS for separating full and empty AAV capsids and quantifying aggregates, establishing it as a key orthogonal method in the field.
• Lipid Nanoparticles (LNPs): A primary technique for characterizing the size, molar mass, and structure of LNP-based drugs, such as mRNA vaccines and siRNA therapeutics.